Back to top
more

QuidelOrtho (QDEL)

(Real Time Quote from BATS)

$23.45 USD

23.45
18,210

+0.01 (0.04%)

Updated Aug 7, 2025 09:58 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech

by Zacks Equity Research

Zacks.com featured highlights include: lululemon, Quidel, China Yuchai and Logitech

Zacks Equity Research

Ecolab Unveils Innovative Tested Tool to Improve Food Safety

by Zacks Equity Research

Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.

Zacks Equity Research

Here's Why You Should Invest in Integer Holdings (ITGR) Stock

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.

Tirthankar Chakraborty headshot

4 Top Efficient Stocks to Boost Your Portfolio

by Tirthankar Chakraborty

A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

Zacks Equity Research

Here's Why You Should Retain NextGen Healthcare (NXGN) Stock

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Zacks Equity Research

Here's Why You Should Invest in DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.

Zacks Equity Research

Here's Why You Should Hold on to Medidata (MDSO) Stock Now

by Zacks Equity Research

Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.

Zacks Equity Research

Here's Why You Should Bet on Merit Medical (MMSI) Stock Now

by Zacks Equity Research

Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.

Zacks Equity Research

Here's Why You Should Consider Betting On CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.

Zacks Equity Research

ABIOMED Gets FDA Confirmation of the Safety of Impella RP

by Zacks Equity Research

ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

Zacks Equity Research

Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring

by Zacks Equity Research

Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) in Your Portfolio

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from its core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

QDEL vs. GNNDY: Which Stock Is the Better Value Option?

by Zacks Equity Research

QDEL vs. GNNDY: Which Stock Is the Better Value Option?

Zacks Equity Research

Quidel (QDEL) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of -11.65% and -6.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Quidel (QDEL) Q1 Earnings Expected to Decline

by Zacks Equity Research

Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment

by Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Lululemon Athletica, Quidel, Kirkland Lake Gold and World Wrestling Entertainment

Tirthankar Chakraborty headshot

4 Must-Buy Efficient Stocks for Your Portfolio

by Tirthankar Chakraborty

A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the company's price performance.

Zacks Equity Research

Quidel (QDEL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Quidel's (QDEL) flagship Triage sees strong growth in China in Q4.

Zacks Equity Research

Quidel (QDEL) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of 29.03% and 0.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quidel (QDEL) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for Cardinal Health's (CAH) Q2 Earnings?

by Zacks Equity Research

Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.

Zacks Equity Research

Here's Why You Should Buy Express Scripts (ESRX) Stock Now

by Zacks Equity Research

Strong demand for Express Scripts' (ESRX) solutions like SafeGuardRx, 90-day supply for chronic medications, exclusive Accredo Specialty Pharmacy and advanced opioid solutions buoy optimism.